FASLG and Venous thrombosis: In this study, the antimalarial drug was protective against thrombosis (HR 0.28, 95% CI 0.08–0.90), while aPL positivity (HR 3.16, 95% CI 1.45–6.88) and previous thrombosis (HR 3.85, 95% CI 1.50–9.91) increased the risk of thrombotic events.